<DOC>
	<DOCNO>NCT00576784</DOCNO>
	<brief_summary>The goal study demonstrate whether switch insulin therapy oral therapy pioglitazone/glimepiride lead deterioration glycemic control ( increase HbA1c 0.5 % ) within 6 month observation period .</brief_summary>
	<brief_title>Metabolic Effects Pioglitazone Type II Diabetic Patients Previously Treated With Insulin</brief_title>
	<detailed_description>To demonstrate reconvert type 2 diabetic patient insulin treatment oral treatment use pioglitazone combination without glimepiride possible without deterioration blood glucose control . Primary aim maintain glycaemic control ( HbA1c ) define increase HbA1c 0.5 % 6 month treatment ( visit 7 ) compare baseline HbA1c value ( screen visit V1 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>type 2 diabetes mellitus insulin therapy &gt; 1 year residual ßcell function ( Cpeptide increase iv glucagon test ) write informed consent type 1 diabetes oral therapy lifethreatening disease heart failure ( NYHA IIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>insulin treatment</keyword>
	<keyword>ß-cell function</keyword>
</DOC>